Loading…
MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases
In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68...
Saved in:
Published in: | Archives of dermatological research 2014-12, Vol.306 (10), p.873-884 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 884 |
container_issue | 10 |
container_start_page | 873 |
container_title | Archives of dermatological research |
container_volume | 306 |
creator | Birner, Peter Berghoff, Anna S Dinhof, Carina Pirker, Christine Capper, David Schoppmann, Sebastian F Petzelbauer, Peter von Deimling, Andreas Berger, Walter Preusser, Matthias |
description | In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chromosome 7p21) and centromere chromosome 7 and immunohistochemistry for ETV1, BRAF (V600E) , and ETV1/BRAF associated proteins pMSK1, pRSK1, pp38, pMEK1/2, MAPKAP kinase 2, CIC, HIF-1alpha and Ki-67. We further studied ETV1 copy number variations in 32 melanoma cell lines from primary and metastatic lesions using array CGH. The influence of the MAP kinase pathway activity on ETV1 mRNA and protein expression under BRAF wild-type and BRAF (V600E) conditions were determined in melanoma cell lines using qRT-PCR and Western Blot. No ETV1 high grade amplifications were observed in tissue samples, but low grade ETV1 gene amplifications were found in 7 (10.3 %) melanoma brain metastases. ETV1 protein expression in tissue samples (15 %) correlated with BRAF (V600E) status (p = 0.007) and HIF-1alpha expression (p = 0.049), but not with ETV1 gene dose. Application of the BRAF(V600E)-specific inhibitor vemurafenib and the BRAF(V6ooE/V600K)-inhibitor dabrafenib revealed predominant regulation of ETV-1 mRNA and protein via MAPK-pathway. ETV1 expression is a rare event in human melanoma and seems to be rather based on hyperactivation of MAPK signals, by BRAF (V600E) mutation, than on ETV1 gene amplification. Consequently, therapeutic inhibition of BRAF and the downstream MAPK pathway also down-regulates oncogenic ETV1 expression. |
doi_str_mv | 10.1007/s00403-014-1490-6 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1625343333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1625343333</sourcerecordid><originalsourceid>FETCH-LOGICAL-p281t-b20623755970ba54310b104db2f14aa590e03902e1ae778c5926d07ed2cbacb63</originalsourceid><addsrcrecordid>eNo1kNtOAkEMhicmRhB9AG_MXOLFauewu-wlElATjMYg8Y50douMsgd3ZlUexPd1QWyaNH_69U9bxs4EXAqA-MoBaFABCB0InUAQHbCu0EoGECUvHXbs3Bu0XDwQR6wjQ4hVDLrLfu6Hj_zdFuiIY-rtp_Ub7pqqKmtPGTcbfv00nPD-PAIYX_C88ehtWfAa_Ypq7ldY8Fcq2uG8WtulTf_a1nF0rkwtbl2-rF_x8WwuOH1XNTm3Qwqe0xqLMkduatxJj65NcifscIlrR6f72mPPk_FsdBtMH27uRsNpUMmB8IGREEkVh2ESg8FQKwFGgM6MXAqNGCZAoBKQJJDay9MwkVEGMWUyNZiaSPVY_8-3qsuPhpxf5NaltG7XorJxCxHJUGm1jR4736ONySlbVLXNsd4s_l-pfgGmQnTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1625343333</pqid></control><display><type>article</type><title>MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases</title><source>Springer Link</source><creator>Birner, Peter ; Berghoff, Anna S ; Dinhof, Carina ; Pirker, Christine ; Capper, David ; Schoppmann, Sebastian F ; Petzelbauer, Peter ; von Deimling, Andreas ; Berger, Walter ; Preusser, Matthias</creator><creatorcontrib>Birner, Peter ; Berghoff, Anna S ; Dinhof, Carina ; Pirker, Christine ; Capper, David ; Schoppmann, Sebastian F ; Petzelbauer, Peter ; von Deimling, Andreas ; Berger, Walter ; Preusser, Matthias</creatorcontrib><description>In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chromosome 7p21) and centromere chromosome 7 and immunohistochemistry for ETV1, BRAF (V600E) , and ETV1/BRAF associated proteins pMSK1, pRSK1, pp38, pMEK1/2, MAPKAP kinase 2, CIC, HIF-1alpha and Ki-67. We further studied ETV1 copy number variations in 32 melanoma cell lines from primary and metastatic lesions using array CGH. The influence of the MAP kinase pathway activity on ETV1 mRNA and protein expression under BRAF wild-type and BRAF (V600E) conditions were determined in melanoma cell lines using qRT-PCR and Western Blot. No ETV1 high grade amplifications were observed in tissue samples, but low grade ETV1 gene amplifications were found in 7 (10.3 %) melanoma brain metastases. ETV1 protein expression in tissue samples (15 %) correlated with BRAF (V600E) status (p = 0.007) and HIF-1alpha expression (p = 0.049), but not with ETV1 gene dose. Application of the BRAF(V600E)-specific inhibitor vemurafenib and the BRAF(V6ooE/V600K)-inhibitor dabrafenib revealed predominant regulation of ETV-1 mRNA and protein via MAPK-pathway. ETV1 expression is a rare event in human melanoma and seems to be rather based on hyperactivation of MAPK signals, by BRAF (V600E) mutation, than on ETV1 gene amplification. Consequently, therapeutic inhibition of BRAF and the downstream MAPK pathway also down-regulates oncogenic ETV1 expression.</description><identifier>EISSN: 1432-069X</identifier><identifier>DOI: 10.1007/s00403-014-1490-6</identifier><identifier>PMID: 25073704</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aged ; Brain Neoplasms - enzymology ; Brain Neoplasms - genetics ; Brain Neoplasms - mortality ; Brain Neoplasms - secondary ; Cell Line, Tumor ; DNA Copy Number Variations ; DNA-Binding Proteins - genetics ; DNA-Binding Proteins - metabolism ; Female ; Gene Dosage ; Gene Expression Regulation, Neoplastic ; Humans ; Imidazoles - pharmacology ; Indoles - pharmacology ; Male ; Melanoma - enzymology ; Melanoma - genetics ; Melanoma - mortality ; Melanoma - secondary ; Middle Aged ; Mitogen-Activated Protein Kinases - metabolism ; Mutation ; Oximes - pharmacology ; Prognosis ; Proportional Hazards Models ; Protein Kinase Inhibitors - pharmacology ; Proto-Oncogene Proteins B-raf - antagonists & inhibitors ; Proto-Oncogene Proteins B-raf - genetics ; Proto-Oncogene Proteins B-raf - metabolism ; RNA, Messenger - metabolism ; Signal Transduction - drug effects ; Skin Neoplasms - enzymology ; Skin Neoplasms - genetics ; Skin Neoplasms - mortality ; Skin Neoplasms - pathology ; Sulfonamides - pharmacology ; Time Factors ; Transcription Factors - genetics ; Transcription Factors - metabolism</subject><ispartof>Archives of dermatological research, 2014-12, Vol.306 (10), p.873-884</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25073704$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Birner, Peter</creatorcontrib><creatorcontrib>Berghoff, Anna S</creatorcontrib><creatorcontrib>Dinhof, Carina</creatorcontrib><creatorcontrib>Pirker, Christine</creatorcontrib><creatorcontrib>Capper, David</creatorcontrib><creatorcontrib>Schoppmann, Sebastian F</creatorcontrib><creatorcontrib>Petzelbauer, Peter</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Berger, Walter</creatorcontrib><creatorcontrib>Preusser, Matthias</creatorcontrib><title>MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases</title><title>Archives of dermatological research</title><addtitle>Arch Dermatol Res</addtitle><description>In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chromosome 7p21) and centromere chromosome 7 and immunohistochemistry for ETV1, BRAF (V600E) , and ETV1/BRAF associated proteins pMSK1, pRSK1, pp38, pMEK1/2, MAPKAP kinase 2, CIC, HIF-1alpha and Ki-67. We further studied ETV1 copy number variations in 32 melanoma cell lines from primary and metastatic lesions using array CGH. The influence of the MAP kinase pathway activity on ETV1 mRNA and protein expression under BRAF wild-type and BRAF (V600E) conditions were determined in melanoma cell lines using qRT-PCR and Western Blot. No ETV1 high grade amplifications were observed in tissue samples, but low grade ETV1 gene amplifications were found in 7 (10.3 %) melanoma brain metastases. ETV1 protein expression in tissue samples (15 %) correlated with BRAF (V600E) status (p = 0.007) and HIF-1alpha expression (p = 0.049), but not with ETV1 gene dose. Application of the BRAF(V600E)-specific inhibitor vemurafenib and the BRAF(V6ooE/V600K)-inhibitor dabrafenib revealed predominant regulation of ETV-1 mRNA and protein via MAPK-pathway. ETV1 expression is a rare event in human melanoma and seems to be rather based on hyperactivation of MAPK signals, by BRAF (V600E) mutation, than on ETV1 gene amplification. Consequently, therapeutic inhibition of BRAF and the downstream MAPK pathway also down-regulates oncogenic ETV1 expression.</description><subject>Adult</subject><subject>Aged</subject><subject>Brain Neoplasms - enzymology</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - secondary</subject><subject>Cell Line, Tumor</subject><subject>DNA Copy Number Variations</subject><subject>DNA-Binding Proteins - genetics</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Female</subject><subject>Gene Dosage</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Imidazoles - pharmacology</subject><subject>Indoles - pharmacology</subject><subject>Male</subject><subject>Melanoma - enzymology</subject><subject>Melanoma - genetics</subject><subject>Melanoma - mortality</subject><subject>Melanoma - secondary</subject><subject>Middle Aged</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>Mutation</subject><subject>Oximes - pharmacology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Proto-Oncogene Proteins B-raf - antagonists & inhibitors</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Proto-Oncogene Proteins B-raf - metabolism</subject><subject>RNA, Messenger - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Skin Neoplasms - enzymology</subject><subject>Skin Neoplasms - genetics</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - pathology</subject><subject>Sulfonamides - pharmacology</subject><subject>Time Factors</subject><subject>Transcription Factors - genetics</subject><subject>Transcription Factors - metabolism</subject><issn>1432-069X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNo1kNtOAkEMhicmRhB9AG_MXOLFauewu-wlElATjMYg8Y50douMsgd3ZlUexPd1QWyaNH_69U9bxs4EXAqA-MoBaFABCB0InUAQHbCu0EoGECUvHXbs3Bu0XDwQR6wjQ4hVDLrLfu6Hj_zdFuiIY-rtp_Ub7pqqKmtPGTcbfv00nPD-PAIYX_C88ehtWfAa_Ypq7ldY8Fcq2uG8WtulTf_a1nF0rkwtbl2-rF_x8WwuOH1XNTm3Qwqe0xqLMkduatxJj65NcifscIlrR6f72mPPk_FsdBtMH27uRsNpUMmB8IGREEkVh2ESg8FQKwFGgM6MXAqNGCZAoBKQJJDay9MwkVEGMWUyNZiaSPVY_8-3qsuPhpxf5NaltG7XorJxCxHJUGm1jR4736ONySlbVLXNsd4s_l-pfgGmQnTA</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Birner, Peter</creator><creator>Berghoff, Anna S</creator><creator>Dinhof, Carina</creator><creator>Pirker, Christine</creator><creator>Capper, David</creator><creator>Schoppmann, Sebastian F</creator><creator>Petzelbauer, Peter</creator><creator>von Deimling, Andreas</creator><creator>Berger, Walter</creator><creator>Preusser, Matthias</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20141201</creationdate><title>MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases</title><author>Birner, Peter ; Berghoff, Anna S ; Dinhof, Carina ; Pirker, Christine ; Capper, David ; Schoppmann, Sebastian F ; Petzelbauer, Peter ; von Deimling, Andreas ; Berger, Walter ; Preusser, Matthias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p281t-b20623755970ba54310b104db2f14aa590e03902e1ae778c5926d07ed2cbacb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Brain Neoplasms - enzymology</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - secondary</topic><topic>Cell Line, Tumor</topic><topic>DNA Copy Number Variations</topic><topic>DNA-Binding Proteins - genetics</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Female</topic><topic>Gene Dosage</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Imidazoles - pharmacology</topic><topic>Indoles - pharmacology</topic><topic>Male</topic><topic>Melanoma - enzymology</topic><topic>Melanoma - genetics</topic><topic>Melanoma - mortality</topic><topic>Melanoma - secondary</topic><topic>Middle Aged</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>Mutation</topic><topic>Oximes - pharmacology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Proto-Oncogene Proteins B-raf - antagonists & inhibitors</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Proto-Oncogene Proteins B-raf - metabolism</topic><topic>RNA, Messenger - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Skin Neoplasms - enzymology</topic><topic>Skin Neoplasms - genetics</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - pathology</topic><topic>Sulfonamides - pharmacology</topic><topic>Time Factors</topic><topic>Transcription Factors - genetics</topic><topic>Transcription Factors - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Birner, Peter</creatorcontrib><creatorcontrib>Berghoff, Anna S</creatorcontrib><creatorcontrib>Dinhof, Carina</creatorcontrib><creatorcontrib>Pirker, Christine</creatorcontrib><creatorcontrib>Capper, David</creatorcontrib><creatorcontrib>Schoppmann, Sebastian F</creatorcontrib><creatorcontrib>Petzelbauer, Peter</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Berger, Walter</creatorcontrib><creatorcontrib>Preusser, Matthias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of dermatological research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Birner, Peter</au><au>Berghoff, Anna S</au><au>Dinhof, Carina</au><au>Pirker, Christine</au><au>Capper, David</au><au>Schoppmann, Sebastian F</au><au>Petzelbauer, Peter</au><au>von Deimling, Andreas</au><au>Berger, Walter</au><au>Preusser, Matthias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases</atitle><jtitle>Archives of dermatological research</jtitle><addtitle>Arch Dermatol Res</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>306</volume><issue>10</issue><spage>873</spage><epage>884</epage><pages>873-884</pages><eissn>1432-069X</eissn><abstract>In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chromosome 7p21) and centromere chromosome 7 and immunohistochemistry for ETV1, BRAF (V600E) , and ETV1/BRAF associated proteins pMSK1, pRSK1, pp38, pMEK1/2, MAPKAP kinase 2, CIC, HIF-1alpha and Ki-67. We further studied ETV1 copy number variations in 32 melanoma cell lines from primary and metastatic lesions using array CGH. The influence of the MAP kinase pathway activity on ETV1 mRNA and protein expression under BRAF wild-type and BRAF (V600E) conditions were determined in melanoma cell lines using qRT-PCR and Western Blot. No ETV1 high grade amplifications were observed in tissue samples, but low grade ETV1 gene amplifications were found in 7 (10.3 %) melanoma brain metastases. ETV1 protein expression in tissue samples (15 %) correlated with BRAF (V600E) status (p = 0.007) and HIF-1alpha expression (p = 0.049), but not with ETV1 gene dose. Application of the BRAF(V600E)-specific inhibitor vemurafenib and the BRAF(V6ooE/V600K)-inhibitor dabrafenib revealed predominant regulation of ETV-1 mRNA and protein via MAPK-pathway. ETV1 expression is a rare event in human melanoma and seems to be rather based on hyperactivation of MAPK signals, by BRAF (V600E) mutation, than on ETV1 gene amplification. Consequently, therapeutic inhibition of BRAF and the downstream MAPK pathway also down-regulates oncogenic ETV1 expression.</abstract><cop>Germany</cop><pmid>25073704</pmid><doi>10.1007/s00403-014-1490-6</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1432-069X |
ispartof | Archives of dermatological research, 2014-12, Vol.306 (10), p.873-884 |
issn | 1432-069X |
language | eng |
recordid | cdi_proquest_miscellaneous_1625343333 |
source | Springer Link |
subjects | Adult Aged Brain Neoplasms - enzymology Brain Neoplasms - genetics Brain Neoplasms - mortality Brain Neoplasms - secondary Cell Line, Tumor DNA Copy Number Variations DNA-Binding Proteins - genetics DNA-Binding Proteins - metabolism Female Gene Dosage Gene Expression Regulation, Neoplastic Humans Imidazoles - pharmacology Indoles - pharmacology Male Melanoma - enzymology Melanoma - genetics Melanoma - mortality Melanoma - secondary Middle Aged Mitogen-Activated Protein Kinases - metabolism Mutation Oximes - pharmacology Prognosis Proportional Hazards Models Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism RNA, Messenger - metabolism Signal Transduction - drug effects Skin Neoplasms - enzymology Skin Neoplasms - genetics Skin Neoplasms - mortality Skin Neoplasms - pathology Sulfonamides - pharmacology Time Factors Transcription Factors - genetics Transcription Factors - metabolism |
title | MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A36%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MAP%20kinase%20activity%20supported%20by%20BRAF%20(V600E)%20mutation%20rather%20than%20gene%20amplification%20is%20associated%20with%20ETV1%20expression%20in%20melanoma%20brain%20metastases&rft.jtitle=Archives%20of%20dermatological%20research&rft.au=Birner,%20Peter&rft.date=2014-12-01&rft.volume=306&rft.issue=10&rft.spage=873&rft.epage=884&rft.pages=873-884&rft.eissn=1432-069X&rft_id=info:doi/10.1007/s00403-014-1490-6&rft_dat=%3Cproquest_pubme%3E1625343333%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p281t-b20623755970ba54310b104db2f14aa590e03902e1ae778c5926d07ed2cbacb63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1625343333&rft_id=info:pmid/25073704&rfr_iscdi=true |